Lab Matters Spring 2017 - Page 19

Automate your syphilis testing with confi dence Fujirebio, makers of SERODIA ® TP·PA, now off ers a fully automated syphilis test on the LUMIPULSE ® G1200 immunoassay system. RESULTS YOU CAN TRUST • Fully automated immunoassay- 120 tests / hour • Less handling with 30 day calibration intervals • Eliminate subjective result interpretation • No Indeterminate Zone Accurate alignment to clinical disease status Using a treponemal test as the initial test followed by a nontreponemal test has been shown in previous studies to increase detection in both primary and latent infections that would otherwise be missed using the traditional testing algorithm. 2,3 Syphilis Stage Primary • Detects IgG and IgM antibodies specifi c for Treponema Pallidum at all stages of syphilis infection through the use of TpN47, Tp15-17 antigens Lumipulse G TP-N Medically Diagnosed Subjects Secondary Latent Treatment Status N Number of Reactive (%) Number of Nonreactive (%) Treated Untreated Treated Untreated Treated Untreated 2 27 25 30 5 200 2 (100%) 27 (100%) 25 (100%) 30 (100%) 5 (100%) 183 (91.5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 17* (8.5%) * 13/17 nonreactive samples tested nonreactive by TP·PA and 15/17 tested nonreactive by RPR. References: 1. Lumipulse G TP-N Immunoreaction Cartridges set Package Insert, Fujirebio Inc. 2. Binnicker, M.J. (2012). Which algorithm should be used to screen for syphilis? Current Opinion in Infectious Diseases, 25 (1), 79-85. 3. Seña A.C., et al. (2010). Novel Treponema pallidum serologic tests: a paradigm shift in syphilis screening for the 21st century. Clinical Infectious Diseases, 51(6), 700-708. Lumipulse is a registered trademark of Fujirebio Inc. ©Fujirebio US, Inc. SERODIA is a registered trademark of Fujirebio, Inc. CONTACT INFORMATION: Fujirebio US, Inc. 205 Great Valley Parkway, Malvern, PA 19355 1-844-544-3787 CustomerSupport.US@Fujirebio.com PublicHealthLabs FDI-443 01/17 @APHL APHL.org Spring 2017 LAB MATTERS 17 1